Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

9.85
-0.3300-3.24%
Post-market: 10.300.4500+4.57%19:59 EST
Volume:2.76M
Turnover:27.22M
Market Cap:857.12M
PE:-3.97
High:10.28
Open:10.22
Low:9.68
Close:10.18
52wk High:12.49
52wk Low:5.41
Shares:87.02M
Float Shares:63.99M
Volume Ratio:1.53
T/O Rate:4.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4801
EPS(LYR):-2.0193
ROE:-65.10%
ROA:-26.57%
PB:3.53
PE(LYR):-4.88

Loading ...

Kura Oncology Chief Medical Officer Mollie Leoni Reports Disposal of Common Shares

Reuters
·
Sep 30

BRIEF-Kura Oncology And Kyowa Kirin Announce First Patient Dosed In Pivotal Phase 3 Komet-017 Trial

Reuters
·
Sep 30

Kura Oncology announces first patient dosed in KOMET-017 clinical trial

TIPRANKS
·
Sep 30

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

GlobeNewswire
·
Sep 30

Kura, Kyowa Kirin Report Ziftomenib Met Primary Endpoint in Phase 2 Leukemia Trial

MT Newswires Live
·
Sep 26

Kura Oncology’s ziftomenib meets primary endpoint in AML study

TIPRANKS
·
Sep 26

Kura Oncology Announces Positive Pivotal Trial Results for Ziftomenib in Relapsed/Refractory NPM1-Mutated AML; FDA Priority Review Underway

Reuters
·
Sep 26

Kura Oncology Inc. to Participate in UBS Virtual Oncology Day Investor Conference

Reuters
·
Sep 24

Jefferies Sticks to Its Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
Sep 18

Barclays Remains a Buy on Kura Oncology (KURA)

TIPRANKS
·
Sep 18

Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Sep 17

Promising Developments in Kura Oncology’s FTI Programs Highlighted by Analyst Buy Rating

TIPRANKS
·
Sep 17

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

GlobeNewswire
·
Sep 17

Troy E. Wilson, President & CEO of Kura Oncology Inc., Reports Acquisition of Common Shares

Reuters
·
Sep 10

Kura Oncology Initiated at Neutral by Guggenheim

Dow Jones
·
Sep 04

Kura Oncology Announces First Clinical Data from Next-Generation Farnesyl Transferase Inhibitor KO-2806 at ESMO Congress 2025

Reuters
·
Sep 03

Kura Oncology Inc. to Participate in Cantor Global Health Conference

Reuters
·
Aug 28

Sector Update: Health Care Stocks Climb Late Afternoon

MT Newswires Live
·
Aug 16

Kura Oncology Shares Rise After CEO Buys Company Shares

MT Newswires Live
·
Aug 16

Kura Oncology Up Over 13%, on Pace for Largest Percent Increase Since January 2024 -- Data Talk

Dow Jones
·
Aug 15